Rate My Professor Todd Bull

Bull maintains an active research laboratory aimed at improving diagnosis and treatment of pulmonary hypertension. His investigations include pulmonary arterial hypertension, pulmonary embolism, pulmonary vascular disease, genomics of pulmonary arterial hypertension, and effects of viral infection on pulmonary hypertension. He participates in clinical trials of novel therapies for PAH and pulmonary embolism. Key publications include "Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results" (2024, European Respiratory Journal), "Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial" (2024, American Journal of Respiratory and Critical Care Medicine), "Right Ventricular Response to Acute Hypoxia among Healthy Humans" (2023, American Journal of Respiratory and Critical Care Medicine), "Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial" (2023, Circulation), and "Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension" (2004, American Journal of Respiratory and Critical Care Medicine). Bull has been recognized repeatedly as a Top Doctor in Denver by 5280 Magazine (2012-2020) in Pulmonary Medicine and Critical Care, Pulmonary Hypertension Physician of the Year by the Pulmonary Hypertension Association (2018), and Physician of the Year by the Colorado Society for Respiratory Care (2013). He is a member of the Clinical Excellence Society in the Department of Medicine.